Mesothelin-ADC - Molecular Diagnostics for Cancer Drug ...

More documents

Recommendations

Info

Agenda Drug Targeting: Antibody Drug Conjugates Rationale and Pre-clinical Results Development Path for a Companion Diagnostic Regulatory Aspects Clinical Development Strategy Page 2 • Mesothelin ADC BAY 94-9343, MipTec 2011 Basel, Sven Golfier
Drug Targeting with an ADC n (2.6 - 4.0) • Mesothelin-ADC: a human IgG 1 conjugated to the maytansinoid antimicrotubule drug DM4 through a cleavable linker • Mode of Action: Targeting tumor antigen mesothelin and delivery of a toxophore acting on proliferating cells. • Pharmacological profile: Tumor growth inhibition of mesothelin-expressing tumors. • ADC promises directed cytotoxicity with minimized off target effects 3 • Mesothelin ADC • Boston, June 2012 • David Henderson
Page 1: Mesothelin-ADC : A Case- Study in E
Page 5 and 6: Literature data on mesothelin expre
Page 7 and 8: Mesothelin-ADC: Anti-Tumor Efficacy
Page 9 and 10: A CDx will be needed for Mesothelin
Page 11 and 12: Companion Diagnostics in Practice I
Page 13 and 14: Parallel development of a therapeut
Page 15 and 16: Development Strategy for Mesothelin
Page 17 and 18: Thanks to the team! Mesothelin-ADC

Mesothelin-ADC - Molecular Diagnostics for Cancer Drug ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?